TABLE 1.

Absolute Benefits and Risks of Antiplatelet Treatment on MI and Major Bleeding Events per 1,000 Patients Treated

Cardiovascular Risk Group*	MIs Prevented	Major Bleeding Incurred
Low (2% per year)	2/1,000	7/1,000
Intermediate (10% per year)	13/1,000	7/1,000
High (25% per year)	32/1,000	7/1,000

Adapted from ref. 25.

^*Low cardiovascular risk: CKD but without clinical evidence for CVD; intermediate cardiovascular risk: CKD and preexisting CVD and/or on dialysis; high cardiovascular risk: CKD and recent acute cardiovascular event.